🚨 $MRNA
— CANCER VACCINE MILESTONE

$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.

🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.

📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.

👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.

#MRNA #Biotech #CancerVaccine #StocksToBinance